CD300LG

CD300LG (nepmucin) is a transmembrane glycoprotein of the capillary endothelium that functions at the interface of vascular transport, immune cell trafficking, and lipid/glucose metabolism. It undergoes bidirectional transcytosis and selectively mediates uptake of IgA2 and IgM across endothelial barriers (PMID:16876123). Its expression on small vessels is constitutive but dynamically regulated by TNF-α, being downregulated in acute inflammation and tumors yet induced on HEV-like vessels in chronically inflamed tissues, consistent with a role in leukocyte transmigration (PMID:24376728). CD300LG influences metabolic homeostasis: a loss-of-function Arg82Cys variant is associated with increased intramyocellular lipid, impaired glucose uptake, and altered HDL metabolism (PMID:26336608, PMID:35382499), while male Cd300lg-knockout mice display impaired glucose tolerance and exercise-induced increases in serum CD300LG are causally linked to glycemic traits by Mendelian randomization (PMID:39190027).

1. 2006 High

   The initial characterization established that CD300LG is an endothelial transmembrane protein capable of bidirectional transcytosis and selective immunoglobulin uptake (IgA2, IgM but not IgG), defining it as a molecular transporter at the capillary barrier rather than a conventional adhesion molecule.

   Evidence Immunoelectron microscopy, polarized MDCK transcytosis assay, and HeLa Ig-uptake assay

   PMID:16876123

   Open questions at the time

   • Identity of the IgA2/IgM-binding domain on CD300LG was not mapped
   • Physiological relevance of Ig transcytosis across native endothelium not demonstrated in vivo
   • No loss-of-function model to confirm transport function
2. 2013 High

   Mapping CD300LG expression across tissues and disease states revealed it is constitutively present on small-vessel endothelium, downregulated by TNF-α and in tumors, and induced on HEV-like vessels during chronic inflammation, establishing it as an inflammation-regulated vascular adhesion/trafficking molecule.

   Evidence Immunohistochemistry across mouse tissues, TNF-α treatment in vivo, NOD diabetes and tumor models

   PMID:24376728

   Open questions at the time

   • The ligand(s) on activated T cells that engage CD300LG remain unidentified
   • Functional consequence of CD300LG loss on lymphocyte trafficking not tested with knockout or blocking antibody
   • Mechanism linking TNF-α signaling to CD300LG downregulation not elucidated
3. 2015 Medium

   A human genetic variant (Arg82Cys) that reduces CD300LG expression was linked to increased intramyocellular lipid and impaired fasting glucose uptake, extending the protein's role from vascular biology into tissue-level lipid and glucose metabolism.

   Evidence Hyperinsulinemic euglycemic clamp, MR spectroscopy, and qPCR/western blot in human muscle and adipose biopsies

   PMID:26336608

   Open questions at the time

   • Single study from one cohort; independent replication of glucose uptake phenotype needed
   • Causal direction between CD300LG expression and intramyocellular lipid accumulation not established
   • Molecular mechanism by which endothelial CD300LG influences myocyte lipid content unknown
4. 2022 Medium

   The same Arg82Cys variant was associated with lower large-HDL cholesterol and ApoA1 levels in males, broadening the metabolic phenotype to include HDL maturation and revealing sex-specificity.

   Evidence Population-based cohort (Oxford BioBank, n=4522) and recall-by-genotype studies with HDL subclass measurements

   PMID:35382499

   Open questions at the time

   • Mechanistic basis for the sex-specific HDL effect not determined
   • Whether CD300LG directly interacts with HDL particles or acts indirectly through endothelial lipid handling is unknown
   • No animal model validation of the HDL phenotype
5. 2024 High

   Combined human exercise-intervention data, Mendelian randomization, and male-specific glucose intolerance in Cd300lg-knockout mice established a causal, sex-dimorphic role for CD300LG in systemic glucose homeostasis and physical activity-induced metabolic adaptation.

   Evidence Serum proteomics after 12-week exercise, hyperinsulinemic clamp, MRI/MRS, mRNA-seq, Mendelian randomization, and Cd300lg-KO mouse glucose tolerance tests

   PMID:39190027

   Open questions at the time

   • Molecular basis of sex-specificity (hormonal regulation, sex-specific interactors) not identified
   • Whether the glucose phenotype reflects endothelial transport of insulin, glucose transporter regulation, or lipid handling is unresolved
   • Tissue-specific conditional knockout not performed
6. 2024 Medium

   CD300LG on tumor-associated monocytes was implicated in contact-dependent reprogramming of CD8+ T cells into central memory-like cells, revealing an immune-modulatory role beyond the endothelium.

   Evidence Single-cell analysis, cell-cell contact assay, and in vivo adoptive transfer/tumor models

   PMID:38386350

   Open questions at the time

   • The ligand on CD8+ T cells that engages monocyte CD300LG is unidentified
   • Whether CD300LG is necessary or merely a marker of the TAMo subset driving reprogramming requires loss-of-function validation
   • Generalizability beyond the specific tumor models tested is unclear
7. 2025 High

   Identification of ApoA4 as a direct binding partner established CD300LG as a receptor for triglyceride-rich lipoproteins at the microvascular endothelium, with knockout mice showing postprandial hypertriglyceridemia independent of LPL, VLDL secretion, or intestinal absorption — providing a unified mechanism for its metabolic phenotypes.

   Evidence (preprint) Cd300lg-KO mouse postprandial lipid assays, direct CD300LG–ApoA4 binding assay, Mendelian randomization linking CD300LG levels to TRL traits and CAD risk

   PMID:bio_10.1101_2025.08.08.669356

   Open questions at the time

   • Preprint not yet peer-reviewed
   • Structural basis of the CD300LG–ApoA4 interaction not resolved
   • Whether ApoA4 binding accounts for all TRL clearance by CD300LG or additional lipoprotein ligands exist is unknown

• Key unresolved questions include the structural basis of CD300LG ligand selectivity (IgA2/IgM vs ApoA4), the mechanism underlying its sex-specific metabolic effects, and whether its endothelial and monocyte functions are mediated by the same or distinct signaling pathways.
• No crystal structure or cryo-EM model of CD300LG or its ligand complexes
• Tissue-specific conditional knockouts needed to dissect endothelial vs. immune cell contributions
• Signaling pathways downstream of CD300LG engagement are entirely uncharacterized